skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

26 Total results for product and free and sample content found

Scrip

Second Genome CEO predicts paradigm shift

22 Mar 2017

Michael Hay, head of Informa Pharma Intelligence Products, shares his thoughts on how shareholder pressure for genuine patient benefits has implications for the pharma and biotech industries.

Scrip

J&J poised to establish no-strings-attached JLABS outside America

16 Mar 2017

As J&J announced the establishment of its eighth JLABS facility, Melinda Richter, head of J&J Innovation, JLABS, says that the company is actively looking to establish JLABS in Europe and Asia.

Scrip

Janssen focuses cardiometabolic R&D on prevention, cure and interception

16 Mar 2017

With readouts in trials of key drugs Invokana and Xarelto coming, Dr. James F. List of Janssen is also looking for assets designed to prevent, cure or even intercept the progression of key diseases such as obesity and NASH.

Scrip

Flexion gears up to commercialize Zilretta

14 Mar 2017

Flexion CEO Mike Clayman shares expectations for regulatory review of recently-filed Zilretta for knee osteoarthritis, and discusses plans for commercialization.

Scrip

Payer environment will impact biopharma prospects in 2017

14 Mar 2017

Michael Hay, head of Informa Pharma Intelligence Products, shares his thoughts on how shareholder pressure for genuine patient benefits has implications for the pharma and biotech industries.

Scrip

Reinventing Arena to focus on Phase II clinical candidates

06 Mar 2017

Dr. Amit Munshi, new CEO of Arena Pharmaceuticals, has already made several changes in the company’s focus and direction.

Scrip

PhaseRx makes more noise than silence with mRNA delivery

06 Mar 2017

PhaseRx president and CEO Dr. Robert Overell explains how delivering messenger RNA inside diseased cells may revolutionize and grow the current USD 4 billion enzyme replacement market.

Scrip

Double barreled approach in glioma patients

01 Mar 2017

Brain cancer remains one of the deadliest diseases, and little to no effective treatments exist.

Scrip

eTheRNA CEO outlines development plan in cancer RNA space

15 Feb 2017

Mike Ward, global director of content for Informa Pharma Intelligence, interviews Dirk Reyn, CEO of eTheRNA, on the sidelines of the BIO-Europe partnering conference in Cologne, Germany. The pair discusses eTheRNA's emerging cancer immunotherapy pipeline, funding prospects and the next steps for the company—which was founded in 2013—as it looks to expand its business.

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888-670-8900
  • US Toll           : +1 908-547-2200
  • UK & Europe : +44 (20) 337 73737
  • Australia       : +61 2 8705 6907

Or email us your inquiry, so we can provide you the best possible customer service:
Pharma@informa.com

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: